SCHEMBL307143

SCHEMBL307143

C[C@@H](N)c1ccc2ccccc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.63
HTR2A P28223 1/20 0.52
HTR2C P28335 1/20 0.52
HTR2B P41595 1/20 0.52
SLC6A2 P23975 4/20 0.49
SLC6A4 P31645 4/20 0.49
SLC6A3 Q01959 4/20 0.49
CYP2D6 P10635 3/20 0.49
CYP3A4 P08684 2/20 0.49
KCNH2 Q12809 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
AOC3 Q16853 2/20 0.49
CYP1A2 P05177 1/20 0.49
TSHR P16473 1/20 0.49
HIF1A Q16665 1/20 0.49
ATM Q13315 1/20 0.48
MMP9 P14780 1/20 0.46
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29463254 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL29350727 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL29471009 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL43789 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL14019306 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL25434816 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL38429 1.00 UGT2B7 (0.63) UGT2B7HTR2AHTR2CHTR2BSLC6A2
Hydrochloric Acid SCHEMBL6417289 0.98 UGT2B7 (0.61) UGT2B7HTR2AHTR2CHTR2BSLC6A2
Ammonia Solution, Strong SCHEMBL27895021 0.98 UGT2B7 (0.61) UGT2B7HTR2AHTR2CHTR2BSLC6A2
SCHEMBL29254013 0.93 UGT2B7 (0.55) UGT2B7HTR2AHTR2CHTR2BSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4624455-A1 PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) 2025-10-01 EP claimed
US-20250276986-A1 PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF Kangbaida (Sichuan) Biotechnology Co., Ltd (CN) 2025-09-04 US claimed
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds LUPIN LIMITED (IN) 2025-07-01 US claimed
CN-114981253-B Process and intermediates for preparing chroman compounds and methods therefor 印度鲁宾有限公司 2024-06-18 CN claimed
WO-2024109801-A1 PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF 成都百裕制药股份有限公司 2024-05-30 WO claimed
CN-118084786-A Schiff base compound, preparation method and application thereof 安徽省东超科技有限公司 2024-05-28 CN claimed
CN-117005018-A Bromine-based two-dimensional chiral perovskite single-crystal nano-sheet and preparation method and application thereof 重庆邮电大学 2023-11-07 CN claimed
CN-114875472-B Organic-inorganic hybrid chiral perovskite helical structure micron sheet and preparation method and application thereof 河南大学 2023-11-03 CN claimed
US-11760750-B1 Process for preparing levoketoconazole NURAY CHEMICALS PRIVATE LIMITED (IN) 2023-09-19 US claimed
CN-116145229-A Chiral material with two-photon absorption characteristic and preparation method thereof 深圳大学 2023-05-23 CN claimed
US-20090281176-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-11-12 US claimed
EP-2098519-A1 Process for the synthesis of ramelteon and its intermediates Teva Pharmaceutical Industries Ltd. (IL) 2009-09-09 EP claimed
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-03-12 US claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US claimed
WO-2007138110-A2 COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY DEVGEN N.V. (BE) 2007-12-06 WO claimed
EP-1819330-A1 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY Devgen N.V. (BE) 2007-08-22 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006058905-A1 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY DEVGEN NV (BE) 2006-06-08 WO claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281176-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES CYP2B6, UGT1A6, CYP2A6 UGT2B7 35/4885HTR2A 2660/4885HTR2C 3006/4885
US-20250276986-A1 PREPARATION METHOD FOR CHIRAL PYRROLE DERIVATIVE AND INTERMEDIATE THEREOF PIN1, DHPS, PPOX UGT2B7 462/4885HTR2A 3309/4885HTR2C 3092/4885
US-20090069581-A1 PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES CYP2B6, UGT1A6, CYP2A6 UGT2B7 51/4885HTR2A 2028/4885HTR2C 2244/4885
US-12344592-B2 Methods, processes and intermediates for preparing chroman compounds CASR, CALCR, RYR1 UGT2B7 1002/4885HTR2A 239/4885HTR2C 193/4885
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 UGT2B7 960/4885HTR2A 695/4885HTR2C 435/4885
US-11760750-B1 Process for preparing levoketoconazole KHK, KYAT3, PLK3 UGT2B7 276/4885HTR2A 3991/4885HTR2C 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.